Vibeke Andersen, Jessica Pingel, Heidi Lynge Søfelt, Zainab Hikmat, Mads Johansson, Vera Slyk Pedersen, Benthe Bertelsen, Anne Carlsson, Marie Lindh, Edda Svavarsdóttir, Dirk Repsilber, Maiken Thyregod Joergensen, Robin Christensen, Anja Fejrskov, Johannes David Füchtbauer, Jens Kjeldsen, Michael Dam Jensen, Claus Aalykke, Martin Rejler, Marte Lie Høivik, Eva Sophia Myers
{"title":"炎症性肠病结果和研究中的性别和两性问题","authors":"Vibeke Andersen, Jessica Pingel, Heidi Lynge Søfelt, Zainab Hikmat, Mads Johansson, Vera Slyk Pedersen, Benthe Bertelsen, Anne Carlsson, Marie Lindh, Edda Svavarsdóttir, Dirk Repsilber, Maiken Thyregod Joergensen, Robin Christensen, Anja Fejrskov, Johannes David Füchtbauer, Jens Kjeldsen, Michael Dam Jensen, Claus Aalykke, Martin Rejler, Marte Lie Høivik, Eva Sophia Myers","doi":"10.1016/s2468-1253(24)00159-6","DOIUrl":null,"url":null,"abstract":"Extensive patient heterogeneity is a challenge in the management of inflammatory bowel disease (IBD). Sex and gender, as well as the interaction of sex and gender with other social identities, referred to as intersectionality, contribute to this heterogeneity and might affect IBD outcomes. An interdisciplinary team of clinicians, researchers, patients, and sex and gender experts reviewed current literature on the effect of sex and gender dimensions on IBD outcomes. The team also investigated the role that stakeholders have in advancing sex-based and gender-based IBD knowledge, as comprehensive studies are scarce. Acknowledging and integrating sex and gender into the organisation and content of research (eg, study design, participant recruitment, data analysis, data interpretation, data dissemination, and impact evaluation) could enhance the validity, relevance, and applicability of research. Such gendered innovation has potential for advancing personalised medicine and improving the quality of life for people with IBD.","PeriodicalId":30,"journal":{"name":"Biomacromolecules","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sex and gender in inflammatory bowel disease outcomes and research\",\"authors\":\"Vibeke Andersen, Jessica Pingel, Heidi Lynge Søfelt, Zainab Hikmat, Mads Johansson, Vera Slyk Pedersen, Benthe Bertelsen, Anne Carlsson, Marie Lindh, Edda Svavarsdóttir, Dirk Repsilber, Maiken Thyregod Joergensen, Robin Christensen, Anja Fejrskov, Johannes David Füchtbauer, Jens Kjeldsen, Michael Dam Jensen, Claus Aalykke, Martin Rejler, Marte Lie Høivik, Eva Sophia Myers\",\"doi\":\"10.1016/s2468-1253(24)00159-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Extensive patient heterogeneity is a challenge in the management of inflammatory bowel disease (IBD). Sex and gender, as well as the interaction of sex and gender with other social identities, referred to as intersectionality, contribute to this heterogeneity and might affect IBD outcomes. An interdisciplinary team of clinicians, researchers, patients, and sex and gender experts reviewed current literature on the effect of sex and gender dimensions on IBD outcomes. The team also investigated the role that stakeholders have in advancing sex-based and gender-based IBD knowledge, as comprehensive studies are scarce. Acknowledging and integrating sex and gender into the organisation and content of research (eg, study design, participant recruitment, data analysis, data interpretation, data dissemination, and impact evaluation) could enhance the validity, relevance, and applicability of research. Such gendered innovation has potential for advancing personalised medicine and improving the quality of life for people with IBD.\",\"PeriodicalId\":30,\"journal\":{\"name\":\"Biomacromolecules\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2024-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomacromolecules\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s2468-1253(24)00159-6\",\"RegionNum\":2,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomacromolecules","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2468-1253(24)00159-6","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Sex and gender in inflammatory bowel disease outcomes and research
Extensive patient heterogeneity is a challenge in the management of inflammatory bowel disease (IBD). Sex and gender, as well as the interaction of sex and gender with other social identities, referred to as intersectionality, contribute to this heterogeneity and might affect IBD outcomes. An interdisciplinary team of clinicians, researchers, patients, and sex and gender experts reviewed current literature on the effect of sex and gender dimensions on IBD outcomes. The team also investigated the role that stakeholders have in advancing sex-based and gender-based IBD knowledge, as comprehensive studies are scarce. Acknowledging and integrating sex and gender into the organisation and content of research (eg, study design, participant recruitment, data analysis, data interpretation, data dissemination, and impact evaluation) could enhance the validity, relevance, and applicability of research. Such gendered innovation has potential for advancing personalised medicine and improving the quality of life for people with IBD.
期刊介绍:
Biomacromolecules is a leading forum for the dissemination of cutting-edge research at the interface of polymer science and biology. Submissions to Biomacromolecules should contain strong elements of innovation in terms of macromolecular design, synthesis and characterization, or in the application of polymer materials to biology and medicine.
Topics covered by Biomacromolecules include, but are not exclusively limited to: sustainable polymers, polymers based on natural and renewable resources, degradable polymers, polymer conjugates, polymeric drugs, polymers in biocatalysis, biomacromolecular assembly, biomimetic polymers, polymer-biomineral hybrids, biomimetic-polymer processing, polymer recycling, bioactive polymer surfaces, original polymer design for biomedical applications such as immunotherapy, drug delivery, gene delivery, antimicrobial applications, diagnostic imaging and biosensing, polymers in tissue engineering and regenerative medicine, polymeric scaffolds and hydrogels for cell culture and delivery.